Scope of Epilepsy Pipeline Review Report H2 2016

Global Markets Direct’s, ‘Epilepsy – Pipeline Review, H2 2016′, provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report on Epilepsy – Pipeline Review, H2 2016′ addition with 110 market data tables and 16  figures, spread across 421 pages is http://www.rnrmarketresearch.com/epilepsy-pipeline-review-h2-2016-market-report.html

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis

Companies Discussed/Mentioned in this Research:

Adamas Pharmaceuticals, Inc , Advicenne, Aeolus Pharmaceuticals, Inc Aequus Pharmaceuticals Inc Aestus Therapeutics, Inc Alexza Pharmaceuticals, Inc Anavex Life Sciences Corp  Asklepios BioPharmaceutical, Inc  Astellas Pharma Inc  Bial – Portela & Ca, S.A  BioCrea GmbH Biogen Inc Bionomics Limited, Biovista Inc  Biscayne Pharmaceuticals, Inc  Catalyst Pharmaceuticals, Inc  D-Pharm Ltd  Eisai Co., Ltd  Glialogix, Inc  Grifols, S.A  GW Pharmaceuticals Plc, H. Lundbeck A/S, Hyundai Pharmaceutical Co., Ltd INSYS Therapeutics, Inc INVENT Pharmaceuticals, Inc  Iproteos S.L  Johnson & Johnson Knopp Biosciences LLC,  Lead Discovery Center GmbH, Lipicard Technologies Limited,  Lotus Pharmaceutical Co., Ltd Marathon Pharmaceuticals, LLC,

Marinus Pharmaceuticals, Inc ,Mitochon Pharmaceuticals, Inc ,Neurelis, Inc ,Neurocrine Biosciences, IncNeuron Biopharma SA,Novartis AG,OPKO Health, Inc ,Ovid Therapeutics Inc ,Pfizer Inc ,PharmatrophiX, Inc,Promius Pharma, LLC,PTC Therapeutics, Inc ,Retrophin Inc ,Sage Therapeutics, IncSaniona AB,SciFluor Life Sciences, LLC,Shire Plc,SK Biopharmaceuticals Co., Ltd,Suda Ltd,Sumitomo Dainippon Pharma Co., Ltd ,Takeda Pharmaceutical Company Limited,Trillium Therapeutics Inc ,Turing Pharmaceuticals AG ,UCB S.A ,Ultragenyx Pharmaceutical Inc ,Upsher-Smith Laboratories, Inc ,Vichem Chemie Research LtdVistaGen Therapeutics , IncVitality Biopharma Inc, Xenon Pharmaceuticals IncXERIS Pharmaceuticals, IncZogenix, IncZynerba Pharmaceuticals, Inc

Inquire before buying for this report  :http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=692215     (This is a premium report price at US$2000 for a single user PDF license).

Scope:                                       

• The report provides a snapshot of the global therapeutic landscape of Epilepsy
• The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
• The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Epilepsy
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.